SGLT2-Inhibition in Patients With Alport Syndrome
Jan Boeckhaus, Daniel P. Gale, James F. Simon, Jie Ding, Yanqin Zhang, Carsten Bergmann, Neil Turner, Matthew Hall, John A. Sayer, Shalabh Srivastava, Hee Gyung Kang, Agne Cerkauskaite-Kerpauskiene, Valentine Gillion, Kathleen Claes, Bastian Krueger, Jonathan de Fallois, Ulrike Walden, Mira Choi, Markus Schueler, Roman-Ulrich Mueller, Polina Todorova, Bernd Hohenstein, Michael Zeisberg, Tim Friede, Bertrand Knebelmann, Jan Halbritter, Oliver Groß
Abstract
Introduction: Large-scale trials showed positive outcomes of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in adults with chronic kidney disease (CKD). Whether the use of SGLT2i is safe and effective in patients with the common hereditary CKD Alport syndrome (AS) has not yet been investigated specifically in larger cohorts. Methods: This observational, multicenter, international study (NCT02378805) assessed 112 patients with AS after start of SGLT2i. The study's primary end point was change of albuminuria in albumin/g creatinine from the start of therapy. Results: = 35). At a total of 71 patient-years at risk, 0.24 adverse events (AEs) per patient-year on SGLT2i were reported. Conclusion: This study indicates that, additive to renin-angiotensin system (RAS)-inhibition (RASi), SGLT2i have the potential to reduce the amount of albuminuria in patients with AS. Future studies are needed to investigate the long-term effects of SGLT2i on CKD progression in patients with AS to assess whether the observed reduction in albuminuria translates to a delay in kidney failure (KF).